2026-2034年全球兒童生長激素缺乏症市場規模、佔有率、趨勢和成長分析報告

兒童生長激素缺乏症的市場規模預計將從 2025 年的 46.6 億美元成長到 2034 年的 230.2 億美元，預計從 2026 年到 2034 年將以 19.43% 的複合年成長率成長。

由於人們對兒童內分泌疾病的認知不斷提高，全球兒童生長激素缺乏症市場正穩定成長。若不及時治療，兒童生長激素缺乏症會導致生長遲緩和發育併發症。小兒科會診的篩檢計畫改善和早期診斷有助於及時介入。醫療保健服務的普及和意識提升也加速了治療的啟動。重組人體生長荷爾蒙療法仍是主要的治療選擇之一。

長效生長激素製劑的技術進步顯著提高了患者的依從性。與每日給藥方案相比，每週一次的注射減輕了治療負擔。已開發國家醫療保健覆蓋範圍的擴大也有助於提高治療的可近性。製藥公司正在投資研發更先進的給藥裝置，例如操作簡單的注射筆。與遺傳和特發性因素相關的荷爾蒙失調發病率的上升進一步推動了市場需求。

未來幾年，緩釋和生物類似生長激素製劑的創新將重塑市場競爭格局。新興市場兒童醫療基礎設施的擴建將創造新的成長機會。基因治療研究的進展或將為未來提供長期解決方案。政府支持兒童健康計畫的政策將進一步提升市場滲透率。整體而言，在內分泌治療解決方案穩步推進的推動下，市場前景依然樂觀。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球兒童生長激素缺乏症市場：按類型分類

• 市場分析、洞察與預測
• 獲得
• 先天性
• 特發性

第5章 全球兒童生長激素缺乏症市場：依治療方法

• 市場分析、洞察與預測
• 生長激素注射
• 其他

第6章 全球兒童生長激素缺乏症市場：依診斷分類

• 市場分析、洞察與預測
• 驗血
• X光檢查
• 電腦斷層掃描
• MRI
• 生長激素刺激試驗
• 其他

第7章 全球兒童生長激素缺乏症市場：依症狀分類

• 市場分析、洞察與預測
• 一張給人青春印象的臉
• 青春期延遲

第8章：全球兒童生長激素缺乏症市場：依體型分類

• 市場分析、洞察與預測
• 毛髮生生長遲緩
• 其他

第9章 全球兒童生長激素缺乏症市場：依劑量分類

• 市場分析、洞察與預測
• 注射
• 其他

第10章 全球兒童生長激素缺乏症市場：依給藥途徑分類

• 市場分析、洞察與預測
• 皮下注射
• 其他

第11章 全球兒童生長激素缺乏症市場：依最終用戶分類

• 市場分析、洞察與預測
• 診所
• 醫院
• 其他

第12章 全球兒童生長激素缺乏症市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第13章 全球兒童生長激素缺乏症市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第14章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第15章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck KGaA
  • Novo Nordisk A/S
  • Genentech Inc
  • Ferring BV
  • Eli Lilly And Company
  • Pfizer Inc
  • Novartis AG
  • Biopartners GmbH
  • F. Hoffmann-La Roche Ltd
  • AnkeBio Co. Ltd
  • GeneScience Pharmaceuticals Co. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Ipsen Pharma
  • LG Chem

The Pediatric Growth Hormone Deficiency Market size is expected to reach USD 23.02 Billion in 2034 from USD 4.66 Billion (2025) growing at a CAGR of 19.43% during 2026-2034.

The Global Pediatric Growth Hormone Deficiency Market is experiencing consistent growth due to rising awareness of childhood endocrine disorders. Growth hormone deficiency in children can lead to delayed growth and developmental complications if untreated. Early diagnosis through improved screening programs and pediatric consultations is supporting timely intervention. Increasing healthcare access and parental awareness are also driving treatment adoption. Recombinant human growth hormone therapies remain the primary treatment option.

Technological advancements in long-acting growth hormone formulations are significantly enhancing patient compliance. Once-weekly injection therapies are reducing treatment burden compared to daily dosing regimens. Expanding healthcare insurance coverage in developed economies is making therapies more accessible. Pharmaceutical companies are investing in improved delivery devices, such as user-friendly injection pens. Rising incidence of hormonal disorders linked to genetic and idiopathic causes is further contributing to market demand.

In the coming years, innovation in sustained-release formulations and biosimilar growth hormone products will shape competitive dynamics. Expanding pediatric healthcare infrastructure in emerging markets will create new growth opportunities. Increased research in gene therapy may offer long-term solutions in the future. Government initiatives supporting child health programs will further strengthen market penetration. Overall, the market outlook remains positive with steady advancements in endocrine treatment solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Acquired
• Congenital
• Idiopathic

By Treatment

• Growth Hormone Shots
• Others

By Diagnosis

• Blood Tests
• X-Ray
• CT Scan
• MRI
• GH Stimulation Test
• Others

By Symptoms

• A Younger-Looking Face
• Delayed Puberty
• A Chubby Body Build
• Impaired Hair Growth
• Others

By Dosage

• Injection
• Others

By Route of Administration

• Subcutaneous
• Others

By End Users

• Clinic
• Hospital
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Merck KGaA, Novo Nordisk AS, Genentech Inc, Ferring BV, Eli Lilly and Company, Pfizer Inc, Novartis AG, Biopartners GmbH, F HoffmannLa Roche Ltd, AnkeBio Co Ltd, GeneScience Pharmaceuticals Co Ltd, Teva Pharmaceutical Industries Ltd, Ipsen Pharma, LG Chem
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Acquired Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Congenital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Idiopathic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Growth Hormone Shots Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY DIAGNOSIS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Diagnosis
• 6.2. Blood Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. X-Ray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CT Scan Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. MRI Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. GH Stimulation Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY SYMPTOMS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Symptoms
• 7.2. A Younger-Looking Face Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Delayed Puberty Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY A CHUBBY BODY BUILD 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast A Chubby Body Build
• 8.2. Impaired Hair Growth Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY DOSAGE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Dosage
• 9.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Route Of Administration
• 10.2. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY END USERS 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast End Users
• 11.2. Clinic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 12.1. Market Analysis, Insights and Forecast Distribution Channel
• 12.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 13. GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET: BY REGION 2022-2034(USD MN)

• 13.1. Regional Outlook
• 13.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.2.1 By Type
  • 13.2.2 By Treatment
  • 13.2.3 By Diagnosis
  • 13.2.4 By Symptoms
  • 13.2.5 By A Chubby Body Build
  • 13.2.6 By Dosage
  • 13.2.7 By Route Of Administration
  • 13.2.8 By End Users
  • 13.2.9 By Distribution Channel
  • 13.2.10 United States
  • 13.2.11 Canada
  • 13.2.12 Mexico
• 13.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.3.1 By Type
  • 13.3.2 By Treatment
  • 13.3.3 By Diagnosis
  • 13.3.4 By Symptoms
  • 13.3.5 By A Chubby Body Build
  • 13.3.6 By Dosage
  • 13.3.7 By Route Of Administration
  • 13.3.8 By End Users
  • 13.3.9 By Distribution Channel
  • 13.3.10 United Kingdom
  • 13.3.11 France
  • 13.3.12 Germany
  • 13.3.13 Italy
  • 13.3.14 Russia
  • 13.3.15 Rest Of Europe
• 13.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.4.1 By Type
  • 13.4.2 By Treatment
  • 13.4.3 By Diagnosis
  • 13.4.4 By Symptoms
  • 13.4.5 By A Chubby Body Build
  • 13.4.6 By Dosage
  • 13.4.7 By Route Of Administration
  • 13.4.8 By End Users
  • 13.4.9 By Distribution Channel
  • 13.4.10 India
  • 13.4.11 Japan
  • 13.4.12 South Korea
  • 13.4.13 Australia
  • 13.4.14 South East Asia
  • 13.4.15 Rest Of Asia Pacific
• 13.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.5.1 By Type
  • 13.5.2 By Treatment
  • 13.5.3 By Diagnosis
  • 13.5.4 By Symptoms
  • 13.5.5 By A Chubby Body Build
  • 13.5.6 By Dosage
  • 13.5.7 By Route Of Administration
  • 13.5.8 By End Users
  • 13.5.9 By Distribution Channel
  • 13.5.10 Brazil
  • 13.5.11 Argentina
  • 13.5.12 Peru
  • 13.5.13 Chile
  • 13.5.14 South East Asia
  • 13.5.15 Rest of Latin America
• 13.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.6.1 By Type
  • 13.6.2 By Treatment
  • 13.6.3 By Diagnosis
  • 13.6.4 By Symptoms
  • 13.6.5 By A Chubby Body Build
  • 13.6.6 By Dosage
  • 13.6.7 By Route Of Administration
  • 13.6.8 By End Users
  • 13.6.9 By Distribution Channel
  • 13.6.10 Saudi Arabia
  • 13.6.11 UAE
  • 13.6.12 Israel
  • 13.6.13 South Africa
  • 13.6.14 Rest of the Middle East And Africa

Chapter 14. COMPETITIVE LANDSCAPE

• 14.1. Recent Developments
• 14.2. Company Categorization
• 14.3. Supply Chain & Channel Partners (based on availability)
• 14.4. Market Share & Positioning Analysis (based on availability)
• 14.5. Vendor Landscape (based on availability)
• 14.6. Strategy Mapping

Chapter 15. COMPANY PROFILES OF GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY INDUSTRY

• 15.1. Top Companies Market Share Analysis
• 15.2. Company Profiles
  • 15.2.1 Merck KGaA
  • 15.2.2 Novo Nordisk A/S
  • 15.2.3 Genentech Inc
  • 15.2.4 Ferring B.V
  • 15.2.5 Eli Lilly And Company
  • 15.2.6 Pfizer Inc
  • 15.2.7 Novartis AG
  • 15.2.8 Biopartners GmbH
  • 15.2.9 F. Hoffmann-La Roche Ltd
  • 15.2.10 AnkeBio Co. Ltd
  • 15.2.11 GeneScience Pharmaceuticals Co. Ltd
  • 15.2.12 Teva Pharmaceutical Industries Ltd
  • 15.2.13 Ipsen Pharma
  • 15.2.14 LG Chem